Eur Rev Med Pharmacol Sci 2022; 26 (10): 3751-3759
DOI: 10.26355/eurrev_202205_28872

Pulmonary embolism in patients with dyspnea after COVID-19 infection

A. Ekici, M. Ekici, A. Baçcıoğlu, F. Akyüz İnanç, H. Aslan

Department of Chest Diseases, Kirikkale University Faculty of Medicine, Yahşihan, Kirikkale, Turkey. mehmetekici_@hotmail.com


OBJECTIVE: Pulmonary embolism as a potential complication that may occur late in the course of COVID-19 cases. The aim of our study is to evaluate the frequency of pulmonary embolism in patients with new or ongoing dyspnea after a COVID-19 infection.

PATIENTS AND METHODS: This is a single-center, prospective observational study to evaluate the clinical and radiological outcomes of consecutive patients presenting outpatient clinic diseases to the chest and a new or ongoing dyspnea after a COVID-19 infection. Demographic, clinical and laboratory data were collected. Dyspnea was evaluated according to the New York Heart Association (NYHA) classification.

RESULTS: Pulmonary embolism was detected in 23.8% (25/105) of patients with new or ongoing dyspnea after a COVID-19 infection. Proportion of pulmonary embolism in patients with NYHA classes I, II, III and IV were respectively 8.7%, 20.0%, 30.0% and 35.3% (p for trend=0.02). Compared to NYHA class I and II patients with dyspnea, those in NYHA classes III and IV showed a higher rate of pulmonary embolism [31.6% vs. 14.6%, OR: 2.7 (1.0 to 7.1), p=0.04, respectively]. In Logistic Procedures, NYHA classes of dyspnea (OR: 4.3, 95% CI: 1.2 to 16.6, p=0.03) (NYHA class III and IV vs. NYHA class I and II) determine the likelihood of pulmonary embolism after COVID-19 infection.

CONCLUSIONS: Pulmonary embolism is common in patients with new or ongoing shortness of breath after a COVID-19 infection. Pulmonary embolism is more likely to develop in patients with higher NYHA classes.

 

Free PDF Download

To cite this article

A. Ekici, M. Ekici, A. Baçcıoğlu, F. Akyüz İnanç, H. Aslan
Pulmonary embolism in patients with dyspnea after COVID-19 infection

Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 10
Pages: 3751-3759
DOI: 10.26355/eurrev_202205_28872